 |
Dr. Michael |
|
| Dusseldorf |
Michael Ruhl is a Dusseldorf, Germany-based Partner with more than 12 years of pharmaceutical industry and consulting experience. Dr. Ruhl focuses on corporate and business unit strategy, new commercial models, R&D-productivity improvement strategies, and strategic risk management for pharmaceutical, diagnostics, and medical technology companies.
Dr. Ruhl’s key areas of expertise include:
-
Health Sector Convergence and Strategic Transformation
-
New Analytics-based Operating Models
-
Functional and Business Unit Performance Improvement
-
R&D-Strategy and Operational/Organizational Re-Design
Some of his most significant assignments have included:
-
Integration of the R&D organizations in a major pharmaceutical industry merger
-
Re-organization of the primary care division of a major pharmaceutical company
-
Development and implementation of a PoC- and Release-for-Sale operating model for a major pharmaceutical company
-
Development and implementation of a next-generation drug safety and regulatory affairs strategy for a major pharmaceutical company
-
Assessment of forward integration strategies and their economic impact for a major medical equipment supplier
-
Strategy development for a major German teaching hospital, incl. establishment of public/private partnershipc with manufacturers/commercial entities
Before joining Booz & Company, Dr. Ruhl worked for Sandoz Pharma AG and was CEO of Cardion AG. He has a Ph.D. in Biochemistry and an MS in Biochemistry from the University of Tübingen.
Additional Information: